Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.~* 18 years or older.~* At least one prior chemotherapy before entering in this trial.~* Not pregnant or breastfeeding.~Exclusion Criteria:~* Prior treatment with cabozantinib.~* Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).~* History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib + Pemetrexed (Type: EXPERIMENTAL): Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).